PBMHealthcare · Biotechnology

PBM Stock Forecast: Psyence Biomedical Ltd. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$4.33

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$16.5M

Ticker Nerd rank

3 / 100

Median analyst target

—

Analysts covering

—

Ticker Nerd rank

PBM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Psyence Biomedical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

3 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Momentum

Revisions

Issuance

Growth

Accruals

Volatility

Quality

Value

Size (90): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PBM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PBM, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBM appears on the weeks it earns a place.

Estimates

PBM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Psyence Biomedical Ltd. (PBM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: —
Price / book: 0.1×
EV / EBITDA: −1.5×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −58.6%
Return on assets: −31.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PBM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
PBMPsyence Biomedical Ltd.	$16.5M	3
PTNPalatin Technologies, Inc.	$16.5M	43
BIVIBioVie, Inc.	$16.5M	22
CTXRCitius Pharmaceuticals, Inc.	$16.5M	20
TPSTTempest Therapeutics, Inc.	$16.6M	36
ADILAdial Pharmaceuticals, Inc.	$16.3M	21
LPCNLipocine, Inc.	$16.8M	36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Psyence Biomedical Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PBM news & analysis

Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development

GlobeNewsWire · 18 Aug 2026positive

Psyence BioMed welcomed the U.S. administration's latest action to accelerate ibogaine development. The company stated that the growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform it has built.

Why it matters — A watcher of Psyence BioMed would care because increased federal support for ibogaine development could align with and potentially benefit the company's existing pharmaceutical platform.

FAQ

Frequently asked questions about PBM stock

How does Ticker Nerd's model rank PBM?

As at 22 Aug 2026, Psyence Biomedical Ltd. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

What is the PBM stock forecast for 2030?

No analyst covering Psyence Biomedical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBM are extrapolating price history, which says nothing about the business.

What does Psyence Biomedical Ltd. do?

Psyence Biomedical Ltd. is a life science biotechnology company focused on developing botanical, nature-derived psilocybin-based psychedelic medicines for mental health disorders.

What is the latest news on PBM?

The most recent item we track (GlobeNewsWire, 18 Aug 2026): "Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development". Psyence BioMed welcomed the U.S. administration's latest action to accelerate ibogaine development. The company stated that the growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform it has built.

Company

About Psyence Biomedical Ltd.

Psyence Biomedical Ltd. is a life science biotechnology company focused on developing botanical, nature-derived psilocybin-based psychedelic medicines for mental health disorders. It specializes in natural psilocybin products aimed at treating psychological trauma, anxiety, depression, adjustment disorder, post-traumatic stress disorder, stress, and grief, particularly in palliative care contexts for patients with incurable cancer diagnoses. The company's lead product candidate, PEX010, is a capsule containing naturally sourced psilocybin under Phase IIb clinical study for psilocybin-assisted psychotherapy. Psyence Biomedical Ltd. operates through an integrated platform encompassing in-house cultivation, manufacturing, and clinical development capabilities. It maintains partnerships, such as with iNGENu Pty Ltd, for advancing clinical trials. As a subsidiary of Psyence Group Inc., it positions itself as a pioneer in evidence-based psychedelic therapeutics targeting unmet needs in palliative care, addiction, and related mental health conditions. Founded in 2021 and headquartered in Toronto, Ontario, Canada, Psyence Biomedical Ltd. plays a role in the emerging field of psychedelic medicine within the biotechnology sector.

CEO Mr. Jody Aufrichtig · 12 employees · Canada · https://psyencebiomed.com